Literature DB >> 16143946

Overlap syndromes.

Ulrich Beuers1, Christian Rust.   

Abstract

In hepatology, the term overlap syndrome describes variant forms of the major hepatobiliary autoimmune diseases, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Patients with overlap syndromes present with both hepatitic and cholestatic biochemical and histological features of AIH, PBC, and/or PSC, and usually show a progressive course toward liver cirrhosis and liver failure without adequate treatment. AIH-PBC overlap syndromes have been reported in almost 10% of adults with AIH or PBC, whereas AIH-PSC overlap syndromes were found in 6 to 8% of children, adolescents, and young adults with AIH or PSC. A minority of patients may also show transition from stable PBC to AIH, AIH to PBC, or AIH to PSC, as documented by single case reports and small case series. Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine. In end-stage disease, liver transplantation is the treatment of choice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143946     DOI: 10.1055/s-2005-916322

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  16 in total

Review 1.  Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management.

Authors:  Fabio Panetta; Valerio Nobili; Maria Rita Sartorelli; Raffaele Edo Papa; Francesca Ferretti; Arianna Alterio; Antonella Diamanti
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Autoimmune hemolityc anemia concomitant with sequential autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Hashimoto's thyroiditis: a new entity of autoimmune polyendocrine syndrome.

Authors:  M Gentile; M Verta; E Vigna; E Lucia; C Mazzone; D Perugini; C Gentile; M G Bisconte; F Romeo; P Leo; C Betterle; F Morabito
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

3.  Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis.

Authors:  Odile Warling; Christophe Bovy; Carla Coïmbra; Timothée Noterdaeme; Jean Delwaide; Edouard Louis
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

Review 5.  Current research on the treatment of primary sclerosing cholangitis.

Authors:  Ahmad H Ali; Elizabeth J Carey; Keith D Lindor
Journal:  Intractable Rare Dis Res       Date:  2015-02

6.  Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance.

Authors:  B Preuss; C Berg; F Altenberend; M Gregor; S Stevanovic; R Klein
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

Review 7.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 8.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 9.  Overlap syndromes among autoimmune liver diseases.

Authors:  Christian Rust; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

10.  IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver.

Authors:  Tom Luedde; Jan Heinrichsdorff; Rossana de Lorenzi; Rita De Vos; Tania Roskams; Manolis Pasparakis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.